Diana E Ramirez-Ardila1, Kirsten Ruigrok-Ritstier2, Jean C Helmijr3, Maxime P Look4, Steven van Laere5, Luc Dirix6, Els M J J Berns7, Maurice P H M Jansen8. 1. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: d.ramirezardila@erasmusmc.nl. 2. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: k.ritstier@erasmusmc.nl. 3. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: j.helmijr@erasmusmc.nl. 4. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: m.look@erasmusmc.nl. 5. Department Oncology, Catholic University Leuven, Leuven, Belgium; Translational Cancer Research Unit, Laboratory of Pathology, Antwerp University, Antwerp, Belgium; Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium. Electronic address: s.vanlaere@gza.be. 6. Translational Cancer Research Unit, Laboratory of Pathology, Antwerp University, Antwerp, Belgium; Oncology Centre, GZA Hospitals St-Augustinus, Antwerp, Belgium. Electronic address: luc.dirix@gza.be. 7. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: p.berns@erasmusmc.nl. 8. Department of Medical Oncology, Erasmus MC - Cancer Institute, Rotterdam, The Netherlands. Electronic address: m.p.h.m.jansen@erasmusmc.nl.
Abstract
BACKGROUND: PIK3CA is the most frequent somatic mutated oncogene in estrogen receptor (ER) positive breast cancer. We previously observed an association between PIK3CA genotype and aromatase inhibitors (AI) treatment outcome. This study now evaluates whether expression of mRNAs and miRs are linked to PIK3CA genotype and are independently related to AI therapy response in order to define potential expressed biomarkers for treatment outcome. MATERIALS AND METHODS: The miR and mRNA expression levels were evaluated for their relationship with the PIK3CA genotype in two breast tumor datasets, i.e. 286 luminal cancers from the TCGA consortium and our set of 84 ER positive primary tumors of metastatic breast cancer patients who received first line AI. BRB Array tools class comparison was performed to define miRs and mRNAs whose expression associate with PIK3CA exon 9 and 20 status. Spearman correlations established miR-mRNA pairs and mRNAs with related expression. Next, a third dataset of 25 breast cancer patients receiving neo-adjuvant letrozole was evaluated, to compare expression levels of identified miRs and mRNAs in biopsies before and after treatment. Finally, to identify potential biomarkers miR and mRNA levels were related with overall survival (OS) and progression free survival (PFS) after first-line AI therapy. RESULTS: Expression of 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) and 9 mRNAs (CCNO, FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, SORBS2, VTCN1) was related to the PIK3CA status in both datasets. All except miR-301a-3p had an increased expression in tumors with PIK3CA mutations. Validation in a publicly available dataset showed that LRG1, PGR, and SERPINA3 levels were decreased after neo-adjuvant AI-treatment. Six miR-mRNA pairs correlated significantly and stepdown analysis of all 12 factors revealed 3 mRNAs (PLCL1, LRG1, FAM81B) related to PFS. Further analyses showed LRG1 and PLCL1 expression to be unrelated with luminal subtype and to associate with OS and with PFS, the latter independent from traditional predictive factors. CONCLUSION: We showed in two datasets of ER positive and luminal breast tumors that the expression of 3 miRs and 9 mRNAs associate with the PIK3CA status. Expression of LRG1 is independent of luminal (A or B) subtype, decreased after neo-adjuvant AI-treatment, and is proposed as potential biomarker for AI therapy outcome.
BACKGROUND:PIK3CA is the most frequent somatic mutated oncogene in estrogen receptor (ER) positive breast cancer. We previously observed an association between PIK3CA genotype and aromatase inhibitors (AI) treatment outcome. This study now evaluates whether expression of mRNAs and miRs are linked to PIK3CA genotype and are independently related to AI therapy response in order to define potential expressed biomarkers for treatment outcome. MATERIALS AND METHODS: The miR and mRNA expression levels were evaluated for their relationship with the PIK3CA genotype in two breast tumor datasets, i.e. 286 luminal cancers from the TCGA consortium and our set of 84 ER positive primary tumors of metastatic breast cancerpatients who received first line AI. BRB Array tools class comparison was performed to define miRs and mRNAs whose expression associate with PIK3CA exon 9 and 20 status. Spearman correlations established miR-mRNA pairs and mRNAs with related expression. Next, a third dataset of 25 breast cancerpatients receiving neo-adjuvant letrozole was evaluated, to compare expression levels of identified miRs and mRNAs in biopsies before and after treatment. Finally, to identify potential biomarkers miR and mRNA levels were related with overall survival (OS) and progression free survival (PFS) after first-line AI therapy. RESULTS: Expression of 3 miRs (miR-449a, miR-205-5p, miR-301a-3p) and 9 mRNAs (CCNO, FAM81B, LRG1, NEK10, PLCL1, PGR, SERPINA3, SORBS2, VTCN1) was related to the PIK3CA status in both datasets. All except miR-301a-3p had an increased expression in tumors with PIK3CA mutations. Validation in a publicly available dataset showed that LRG1, PGR, and SERPINA3 levels were decreased after neo-adjuvant AI-treatment. Six miR-mRNA pairs correlated significantly and stepdown analysis of all 12 factors revealed 3 mRNAs (PLCL1, LRG1, FAM81B) related to PFS. Further analyses showed LRG1 and PLCL1 expression to be unrelated with luminal subtype and to associate with OS and with PFS, the latter independent from traditional predictive factors. CONCLUSION: We showed in two datasets of ER positive and luminal breast tumors that the expression of 3 miRs and 9 mRNAs associate with the PIK3CA status. Expression of LRG1 is independent of luminal (A or B) subtype, decreased after neo-adjuvant AI-treatment, and is proposed as potential biomarker for AI therapy outcome.
Authors: Matthew J Ellis; Li Ding; Dong Shen; Jingqin Luo; Vera J Suman; John W Wallis; Brian A Van Tine; Jeremy Hoog; Reece J Goiffon; Theodore C Goldstein; Sam Ng; Li Lin; Robert Crowder; Jacqueline Snider; Karla Ballman; Jason Weber; Ken Chen; Daniel C Koboldt; Cyriac Kandoth; William S Schierding; Joshua F McMichael; Christopher A Miller; Charles Lu; Christopher C Harris; Michael D McLellan; Michael C Wendl; Katherine DeSchryver; D Craig Allred; Laura Esserman; Gary Unzeitig; Julie Margenthaler; G V Babiera; P Kelly Marcom; J M Guenther; Marilyn Leitch; Kelly Hunt; John Olson; Yu Tao; Christopher A Maher; Lucinda L Fulton; Robert S Fulton; Michelle Harrison; Ben Oberkfell; Feiyu Du; Ryan Demeter; Tammi L Vickery; Adnan Elhammali; Helen Piwnica-Worms; Sandra McDonald; Mark Watson; David J Dooling; David Ota; Li-Wei Chang; Ron Bose; Timothy J Ley; David Piwnica-Worms; Joshua M Stuart; Richard K Wilson; Elaine R Mardis Journal: Nature Date: 2012-06-10 Impact factor: 49.962
Authors: Christopher R Smith; Ihor Batruch; Josep Miquel Bauça; Hari Kosanam; Julia Ridley; Marcus Q Bernardini; Felix Leung; Eleftherios P Diamandis; Vathany Kulasingam Journal: Clin Proteomics Date: 2014-06-02 Impact factor: 3.988
Authors: Nicole M Davis Armstrong; Wei-Min Chen; Michael S Brewer; Stephen R Williams; Michèle M Sale; Bradford B Worrall; Keith L Keene Journal: Front Genet Date: 2018-09-06 Impact factor: 4.599
Authors: Carlotta Camilli; Alexandra E Hoeh; Giulia De Rossi; Stephen E Moss; John Greenwood Journal: J Biomed Sci Date: 2022-01-21 Impact factor: 12.771